Olanzapine and Fluoxetine

Antidepressant · SSRIs/Thienobenzodiazepine

Indications

Bipolar 1 Disorder, treatment of resistant depression, anxiety disorders, eating disorders, obsessive compulsive disorder, post-traumatic stress disorder.

Dosage

Adults: Depression associated with Bipolar1 disorder: Initial 25 mg/6 mg per day in evening. Max 75 mg/18 mg per day. Treatment resistant depression: Initial 25 mg/6 mg per day in evening. Max 75 mg/18 mg per day.

Adverse Effects

Suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision.

Risk Factor (Pregnancy/Lactation)

Precautions: Allergy, breast cancer, intestinal problems, kidney disease, liver problems, low blood pressure, neuroleptic malignant syndrome, narrow-angle glaucoma, prostate problem, seizures, stomach problems, dehydration, dementia, stroke, low white blood cell.

Advice to Patient

Take with or without meals. Change position slowly from sitting or lying to standing. Do not stop taking medication abruptly, gradually decrease the dose and then stop. Contact prescriber if there is dizziness, severe headache, lightheadedness, drowsiness, diarrhea, dry mouth, constipation, increased appetite, weight gain, difficulty in sleeping, changes in behaviour, suicidal thoughts, swelling of hands or ankles or feet, restlessness, difficulty in urination, altered sexual ability, dark stools, easy bruising or bleeding, severe vomiting, yellowing of eyes or skin, seizures, eye pain/swelling/redness, severe abdominal pain, slow heartbeat, fever, constant sore throat, changes in vision, increased thirst or unusual weakness.

Pharmacokinetics

OLANZAPINE: Onset of action: Within 1 to 2 weeks for control of aggression, agitation, insomnia; 3 to 6 weeks for control of mania and positive psychotic symptoms. Adequate trial: Typically 6 weeks at maximum tolerated doses. Absorption: Oral: Well absorbed; not affected by food. Short-acting injection: Rapidly absorbed. Metabolism: Hepatic. Half-life elimination: Oral and IM (short-acting): Children: (10 to 18 years; n=8): 37.2 ± 5.1 hours; Adults: 30 hours (21 to 54 hours (5th to 95th percentile)]; approximately 1.5 times greater in elderly. Extended-release injection: Approx.30 days. Time to peak, plasma: Maximum plasma concentrations after IM administration are 5 times higher than maximum plasma concentrations produced by an oral dose. Extended-release injection: Approx.7 day. Short-acting injection: 15 to 45 minutes. Oral: Children (10 to 18 years; n=8): 47 ± 3.7 hours; Adults:…

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.